Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. We are pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. As an operating subsidiary of Purdue Pharma L.P., Imbrium strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians and health systems worldwide. We have built a robust and diversified pipeline of investigational drug candidates, and we actively collaborate with industry and academic partners to identify and advance future impactful medicines.
LinkedIn posts may include discussion of investigational products that have not been approved by FDA, and for which safety or effectiveness have not been established. There is no guarantee they will successfully complete development or gain FDA approval.
Company Details
- Employees
- 31
- Founded
- -
- Address
- 201 Tresser Boulevard, Stamford,ct 06901,united States
- Phone
- +1-888-827-0622
- co****@****era.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- imbriumthera.com
- Keywords
- Representative jobs.
- HQ
- Stamford, CT
Imbrium Therapeutics Questions
Imbrium Therapeutics's helpline number is +1-888-827-0622
Imbrium Therapeutics's website is imbriumthera.com
Imbrium Therapeutics's LinkedIn profile is https://www.linkedin.com/company/imbrium-therapeutics
Imbrium Therapeutics has
31 employees.
View email and phone details for 31
employees at Imbrium Therapeutics.
Imbrium Therapeutics's industry is
Biotechnology Research
Imbrium Therapeutics's top competitors are
Osmol Therapeutics,
Adlon Therapeutics,
Purdue Pharma L.p.,
Merion West,
Allyx Therapeutics,
Intensity Therapeutics, Inc.,
Trevi Therapeutics, Inc.,
Sca Pharma,
Bioxcel Therapeutics, Inc.,
Thetis Pharmaceuticals.
Imbrium Therapeutics's support email address is contactus@imbriumthera.com
Imbrium Therapeutics's categories are Biotechnology Research
Imbrium Therapeutics's founding year is 2018
